Prediction of chemical-protein interactions network with weighted network-based inference method

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Cheng, Feixiong ^a   Zhou, Yadi ^a   Li, Weihua ^a   Liu, Guixia ^a   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; G PROTEIN COUPLED RECEPTOR; IMATINIB; OLANZAPINE; SERTINDOLE; ZIPRASIDONE;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CHEMICAL INTERACTION; CHEMICAL PROTEIN INTERACTION; DATA BASE; DRUG BASED SIMILARITY INFERENCE; DRUG REPOSITIONING; EDGE WEIGHTED NETWORK BASED INFERENCE; MATHEMATICAL ANALYSIS; NETWORK BASED INFERENCE; NODE WEIGHTED NETWORK BASED INFERENCE; POLYPHARMACY; PREDICTION; PROTEIN INTERACTION; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; TARGET BASED SIMILARITY INFERENCE; VALIDATION PROCESS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BINDING SITES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, STATISTICAL; MODELS, THEORETICAL; PROTEIN INTERACTION MAPS; PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84864003584     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041064     Document Type: Article

References (63)

1. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
2. Schilsky RL, Allen J, Benner J, Sigal E, McClellan M, (2010) Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist 15: 484-487.
3. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M, (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
4. Uliana SR, Barcinski MA, (2009) Repurposing for neglected diseases. Science 326: 935.
5. Ashburn TT, Thor KB, (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683.
6. Gonzalez-Diaz H, Prado-Prado F, Garcia-Mera X, Alonso N, Abeijon P, et al. (2011) MIND-BEST: Web Server for Drugs and Target Discovery; Design, Synthesis, and Assay of MAO-B Inhibitors and Theoretical-Experimental Study of G3PDH Protein from Trichomonas gallinae. J Proteome Res 10: 1698-1718.
7. Li H, Gao Z, Kang L, Zhang H, Yang K, et al. (2006) TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 34: W219-224.
8. Luo H, Chen J, Shi L, Mikailov M, Zhu H, et al. (2011) DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res 39: W492-498.
9. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M, (2008) Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24: i232-240.
10. Yabuuchi H, Niijima S, Takematsu H, Ida T, Hirokawa T, et al. (2011) Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol Syst Biol 7: 472.
11. Wang F, Liu D, Wang H, Luo C, Zheng M, et al. (2011) Computational screening for active compounds targeting protein sequences: methodology and experimental validation. J Chem Inf Model 51: 2821-2828.
12. van Westen GJ, Wegner J, Ijzerman AP, van Vlijmen HW, Bender A, (2011) Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. Med Chem Commun 2: 16-30.
13. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621-14626.
14. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, et al. (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3: 96ra76.
15. Barabasi AL, Gulbahce N, Loscalzo J, (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12: 56-68.
16. Zhang SD, Lu WQ, Liu XF, Diao YY, Bai F, et al. (2011) Fast and effective identification of the bioactive compounds and their targets form the medicinal plants via computational chemical biology approach. Med Chem Comm 2: 471-477.
17. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science 321: 263-266.
18. Faulon JL, Misra M, Martin S, Sale K, Sapra R, (2008) Genome scale enzyme-metabolite and drug-target interaction predictions using the signature molecular descriptor. Bioinformatics 24: 225-233.
19. Jacob L, Vert JP, (2008) Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics 24: 2149-2156.
20. Bleakley K, Yamanishi Y, (2009) Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 25: 2397-2403.
21. Yamanishi Y, Kotera M, Kanehisa M, Goto S, (2010) Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26: i246-254.
22. van Laarhoven T, Nabuurs SB, Marchiori E, (2011) Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 27: 3036-3043.
23. Cheng FX, Zhou YD, Li J, Li WH, Liu GX, et al. (2012) Prediction of Chemical-Protein Interactions: Multitarget-QSAR versus Computational Chemogenomic Methods. Mol BioSyst, in press doi:101039/C2MB25110H.
24. Zhou T, Kuscsik Z, Liu JG, Medo M, Wakeling JR, et al. (2010) Solving the apparent diversity-accuracy dilemma of recommender systems. Proc Natl Acad Sci USA 107: 4511-4515.
25. Zhou T, Su RQ, Liu RR, Jiang LL, Wang BH, et al. (2009) Accurate and diverse recommendations via eliminating redundant correlations. New J Phys 11: 123008.
26. Cheng FX, Liu C, Jiang J, Lu WQ, Li WH, et al. (2012) Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference. PLoS Comput Biol 8: e1002503.
27. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-1107.
28. Open Babel (version 2.3.0). (Access Date: Apr. 18, 2010).
29. Willett P, (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11: 1046-1053.
30. Smith TF, Waterman MS, (1981) Identification of common molecular subsequences. J Mol Biol 147: 195-197.
31. Jia C, RR L, D S, Wang B, (2008) A new weighting method in network-based recommendation. Physica A 387: 5887-5891.
32. Bamborough P, Drewry D, Harper G, Smith GK, Schneider K, (2008) Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem 51: 7898-7914.
33. Varnek A, Tropsha A, (2008) Chemoinformatics: An Approach to Virtual Screening. Cambridge, UK: R. Soc. Chem.
34. Sadowski MI, Jones DT, (2009) The sequence-structure relationship and protein function prediction. Curr Opin Struct Biol 19: 357-362.
35. Csermely P, (2004) Strong links are important, but weak links stabilize them. Trends Biochem Sci 29: 331-334.
36. Linyuan L, Tao Z, (2010) Link prediction in weighted networks: The role of weak ties. EPL 89: P18001-P18006.
37. Granovetter M, (1973) The strength of weak ties. Am J Sociol 78: 1360-1380.
38. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-1041.
39. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
40. Deininger MW, Druker BJ, (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55: 401-423.
41. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, et al. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
42. Chen Z, Lee FY, Bhalla KN, Wu J, (2006) Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 69: 1527-1533.
43. Quintas-Cardama A, Kantarjian H, Cortes J, (2006) Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol 2: 655-665.
44. Lindstrom E, Levander S, (2006) Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother 7: 1825-1834.
45. Nasrallah HA, (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13: 27-35.
46. Chen X, Ji ZL, Chen YZ, (2002) TTD: Therapeutic Target Database. Nucleic Acids Res 30: 412-415.
47. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J, (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71: 521-529.
48. Iskar M, Zeller G, Zhao XM, van Noort V, Bork P, (2011) Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol. 23: 1-8 doi:10.1016/j.copbio.2011.11.010.
49. Gottlieb A, Stein GY, Ruppin E, Sharan R, (2011) PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 7: 496.
50. Cami A, Arnold A, Manzi S, Reis B, (2011) Predicting adverse drug events using pharmacological network models. Sci Transl Med 3: 114ra127.
51. Knight ZA, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137.
52. Sawyers CL, (2007) Cancer: mixing cocktails. Nature 449: 993-996.
53. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336.
54. Overington JP, Al-Lazikani B, Hopkins AL, (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
55. Imming P, Sinning C, Meyer A, (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5: 821-834.
56. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH, (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359: 1577-1578.
57. Xie L, Kinnings SL, Bourne PE, (2012) Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 52: 361-379.
58. Korcsmaros T, Szalay MS, Bode C, Kovacs IA, Csermely P, (2007) How to design multi-target drugs: Target search options in cellular networks. Expert Opin Drug Discovery 2: 799-808.
59. Akitaya T, Seno A, Nakai T, Hazemoto N, Murata S, et al. (2007) Weak interaction induces an ON/OFF switch, whereas strong interaction causes gradual change: folding transition of a long duplex DNA chain by poly-L-lysine. Biomacromolecules 8: 273-278.
60. D'Ari R, Casadesus J, (1998) Underground metabolism. Bioessays 20: 181-186.
61. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, et al. (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101: 5328-5335.
62. Gleeson MP, Hersey A, Montanari D, Overington J, (2011) Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 10: 197-208.
63. Youdim MB, Buccafusco JJ, (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26: 27-35.